THERAPIES BORN FROM THE SCIENCE OF PLASMA™ Therapies Born from the Science of Aging® Alkahest is a clinical stage biopharmaceutical company targeting neurodegenerative and age-related diseases with transformative therapies derived from a deep understanding of the plasma proteome in aging and disease. Harnessing Chronokines Aging is the dominant risk factor in degenerative diseases, particularly those with no or few therapeutic solutions. Alkahest is decoding the plasma proteome to create groundbreaking therapies that halt or reverse these harmful effects of aging in critical diseases. Our unique approach capitalizes on the body’s natural vehicle of communication: the plasma proteome. Targeting specific chronokines, the proteins that increase or decrease with age, allows us to create therapeutics that modulate a wide range of deleterious age-related disease mechanisms with unique precision. These include Alzheimer’s disease, Parkinson’s disease, Age-related Macular Degeneration (AMD) and others. Chronokines as Therapeutic Targets We are developing clinical candidates that increase or decrease the levels of key circulating chronokines to either promote innate and natural restorative biological processes or inhibit pathological degenerative processes. Our therapeutics include both traditional pharmaceutical modalities as well as highly selected and refined plasma fractions and other methods for antagonizing or supplementing the most biologically active chronokines. Targeting the Diseases of Our Future Product Indication Research IND Enabling Phase 1 Phase 2 Phase 3 AKST4290 WetAMD Parkinson's Disease (partnered with MJFF) Inflammatory Disease AKST/GRF6019/6021 Alzheimer's Disease - Mild to Moderate Alzheimer's Disease - Severe Parkinson's Disease with Cognitive Impairment Postoperative Recovery AKST1210 End Stage Renal Disease related Cognitive Impairment Novel Factors Undisclosed News & Media July 28, 2021 Alkahest Strengthens Management Team with Addition of César Cerezo as Chief Medical Officer March 10, 2021 Alkahest to Present Positive Data from Completed Phase 2 Clinical Trial at the 15th International Conference on Alzheimer’s and Parkinson’s Disease September 7, 2020 Grifols to acquire Alkahest to enhance discovery research and development to identify innovative therapies for age-related diseases based upon an understanding of the human plasma proteome © 2021 Alkahest, Inc. All rights reserved. All images property of their respective owners. Cookie Policy. Therapies Born from the Science of Plasma™ , in accordance with our cookie policy. I Understand